Unmet Needs in the Treatment of Lung Cancer - Episode 19
For High-Definition, Click
H. Jack West, MD, discusses the growing number of targeted therapies becoming available as treatments for patients with non-small cell lung cancer (NSCLC). This field began with EGFR and ALK inhibitors and was quickly expanded to ROS1. Additionally, the targets for therapies are still expanding further into HER2, BRAF, MET, and others.
Each of these targeted agents is for small patient populations of 1% to 3%; however, as more agents are found, this benefit begins to add up toward a large section of the total population. Future advances in this field are eagerly anticipated.